These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
179 related articles for article (PubMed ID: 33051313)
1. Blood functional assay for rapid clinical interpretation of germline Raad S; Rolain M; Coutant S; Derambure C; Lanos R; Charbonnier F; Bou J; Bouvignies E; Lienard G; Vasseur S; Farrell M; Ingster O; Baert Desurmont S; Kasper E; Bougeard G; Frébourg T; Tournier I J Med Genet; 2021 Dec; 58(12):796-805. PubMed ID: 33051313 [TBL] [Abstract][Full Text] [Related]
2. Cancer incidence, patterns, and genotype-phenotype associations in individuals with pathogenic or likely pathogenic germline TP53 variants: an observational cohort study. de Andrade KC; Khincha PP; Hatton JN; Frone MN; Wegman-Ostrosky T; Mai PL; Best AF; Savage SA Lancet Oncol; 2021 Dec; 22(12):1787-1798. PubMed ID: 34780712 [TBL] [Abstract][Full Text] [Related]
3. Germline TP53 mutations result into a constitutive defect of p53 DNA binding and transcriptional response to DNA damage. Zerdoumi Y; Lanos R; Raad S; Flaman JM; Bougeard G; Frebourg T; Tournier I Hum Mol Genet; 2017 Jul; 26(14):2591-2602. PubMed ID: 28369373 [TBL] [Abstract][Full Text] [Related]
4. Biochemical and imaging surveillance in germline TP53 mutation carriers with Li-Fraumeni syndrome: 11 year follow-up of a prospective observational study. Villani A; Shore A; Wasserman JD; Stephens D; Kim RH; Druker H; Gallinger B; Naumer A; Kohlmann W; Novokmet A; Tabori U; Tijerin M; Greer ML; Finlay JL; Schiffman JD; Malkin D Lancet Oncol; 2016 Sep; 17(9):1295-305. PubMed ID: 27501770 [TBL] [Abstract][Full Text] [Related]
5. Comprehensive detection of germline variants by MSK-IMPACT, a clinical diagnostic platform for solid tumor molecular oncology and concurrent cancer predisposition testing. Cheng DT; Prasad M; Chekaluk Y; Benayed R; Sadowska J; Zehir A; Syed A; Wang YE; Somar J; Li Y; Yelskaya Z; Wong D; Robson ME; Offit K; Berger MF; Nafa K; Ladanyi M; Zhang L BMC Med Genomics; 2017 May; 10(1):33. PubMed ID: 28526081 [TBL] [Abstract][Full Text] [Related]
6. Breast cancer patients suggestive of Li-Fraumeni syndrome: mutational spectrum, candidate genes, and unexplained heredity. Penkert J; Schmidt G; Hofmann W; Schubert S; Schieck M; Auber B; Ripperger T; Hackmann K; Sturm M; Prokisch H; Hille-Betz U; Mark D; Illig T; Schlegelberger B; Steinemann D Breast Cancer Res; 2018 Aug; 20(1):87. PubMed ID: 30086788 [TBL] [Abstract][Full Text] [Related]
7. A substantial proportion of apparently heterozygous TP53 pathogenic variants detected with a next-generation sequencing hereditary pan-cancer panel are acquired somatically. Coffee B; Cox HC; Bernhisel R; Manley S; Bowles K; Roa BB; Mancini-DiNardo D Hum Mutat; 2020 Jan; 41(1):203-211. PubMed ID: 31490007 [TBL] [Abstract][Full Text] [Related]
8. Terradas M; Mur P; Belhadj S; Woodward ER; Burghel GJ; Munoz-Torres PM; Quintana I; Navarro M; Brunet J; Lazaro C; Pineda M; Moreno V; Capella G; Evans DGR; Valle L Gut; 2021 Jun; 70(6):1139-1146. PubMed ID: 32998877 [TBL] [Abstract][Full Text] [Related]
9. p53 major hotspot variants are associated with poorer prognostic features in hereditary cancer patients. Fortuno C; Pesaran T; Dolinsky J; Yussuf A; McGoldrick K; Kho PF; James PA; Spurdle AB Cancer Genet; 2019 Jun; 235-236():21-27. PubMed ID: 31296311 [TBL] [Abstract][Full Text] [Related]
10. Prevalence of low-penetrant germline TP53 D49H mutation in Japanese cancer patients. Yamaguchi K; Urakami K; Nagashima T; Shimoda Y; Ohnami S; Ohnami S; Ohshima K; Mochizuki T; Hatakeyama K; Serizawa M; Akiyama Y; Maruyama K; Katagiri H; Ishida Y; Takahashi K; Nishimura S; Terashima M; Kawamura T; Kinugasa Y; Yamakawa Y; Onitsuka T; Ohde Y; Sugino T; Ito I; Matsubayashi H; Horiuchi Y; Mizuguchi M; Yamazaki M; Inoue K; Wakamatsu K; Sugiyama M; Uesaka K; Kusuhara M Biomed Res; 2016; 37(4):259-64. PubMed ID: 27545002 [TBL] [Abstract][Full Text] [Related]
11. Functional characterization of novel germline TP53 variants in Swedish families. Kharaziha P; Ceder S; Axell O; Krall M; Fotouhi O; Böhm S; Lain S; Borg Å; Larsson C; Wiman KG; Tham E; Bajalica-Lagercrantz S Clin Genet; 2019 Sep; 96(3):216-225. PubMed ID: 31081129 [TBL] [Abstract][Full Text] [Related]
13. Dominant-negative features of mutant TP53 in germline carriers have limited impact on cancer outcomes. Monti P; Perfumo C; Bisio A; Ciribilli Y; Menichini P; Russo D; Umbach DM; Resnick MA; Inga A; Fronza G Mol Cancer Res; 2011 Mar; 9(3):271-9. PubMed ID: 21343334 [TBL] [Abstract][Full Text] [Related]
14. Super-Transactivation TP53 Variant in the Germline of a Family with Li-Fraumeni Syndrome. Id Said B; Kim H; Tran J; Novokmet A; Malkin D Hum Mutat; 2016 Sep; 37(9):889-92. PubMed ID: 27297285 [TBL] [Abstract][Full Text] [Related]
15. TP53 Germline Variations Influence the Predisposition and Prognosis of B-Cell Acute Lymphoblastic Leukemia in Children. Qian M; Cao X; Devidas M; Yang W; Cheng C; Dai Y; Carroll A; Heerema NA; Zhang H; Moriyama T; Gastier-Foster JM; Xu H; Raetz E; Larsen E; Winick N; Bowman WP; Martin PL; Mardis ER; Fulton R; Zambetti G; Borowitz M; Wood B; Nichols KE; Carroll WL; Pui CH; Mullighan CG; Evans WE; Hunger SP; Relling MV; Loh ML; Yang JJ J Clin Oncol; 2018 Feb; 36(6):591-599. PubMed ID: 29300620 [TBL] [Abstract][Full Text] [Related]
16. Combined effects of single nucleotide polymorphisms TP53 R72P and MDM2 SNP309, and p53 expression on survival of breast cancer patients. Schmidt MK; Tommiska J; Broeks A; van Leeuwen FE; Van't Veer LJ; Pharoah PD; Easton DF; Shah M; Humphreys M; Dörk T; Reincke SA; Fagerholm R; Blomqvist C; Nevanlinna H Breast Cancer Res; 2009; 11(6):R89. PubMed ID: 20021639 [TBL] [Abstract][Full Text] [Related]
17. Prevalence of germline TP53 mutations in HER2+ breast cancer patients. Rath MG; Masciari S; Gelman R; Miron A; Miron P; Foley K; Richardson AL; Krop IE; Verselis SJ; Dillon DA; Garber JE Breast Cancer Res Treat; 2013 May; 139(1):193-8. PubMed ID: 23580068 [TBL] [Abstract][Full Text] [Related]
18. Genotype-phenotype correlations among TP53 carriers: Literature review and analysis of probands undergoing multi-gene panel testing and single-gene testing. Fortuno C; Pesaran T; Mester J; Dolinsky J; Yussuf A; McGoldrick K; James PA; Spurdle AB Cancer Genet; 2020 Oct; 248-249():11-17. PubMed ID: 32966936 [TBL] [Abstract][Full Text] [Related]
19. TP53 germline mutation testing in 180 families suspected of Li-Fraumeni syndrome: mutation detection rate and relative frequency of cancers in different familial phenotypes. Ruijs MW; Verhoef S; Rookus MA; Pruntel R; van der Hout AH; Hogervorst FB; Kluijt I; Sijmons RH; Aalfs CM; Wagner A; Ausems MG; Hoogerbrugge N; van Asperen CJ; Gomez Garcia EB; Meijers-Heijboer H; Ten Kate LP; Menko FH; van 't Veer LJ J Med Genet; 2010 Jun; 47(6):421-8. PubMed ID: 20522432 [TBL] [Abstract][Full Text] [Related]
20. Contribution of de novo and mosaic Renaux-Petel M; Charbonnier F; Théry JC; Fermey P; Lienard G; Bou J; Coutant S; Vezain M; Kasper E; Fourneaux S; Manase S; Blanluet M; Leheup B; Mansuy L; Champigneulle J; Chappé C; Longy M; Sévenet N; Paillerets BB; Guerrini-Rousseau L; Brugières L; Caron O; Sabourin JC; Tournier I; Baert-Desurmont S; Frébourg T; Bougeard G J Med Genet; 2018 Mar; 55(3):173-180. PubMed ID: 29070607 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]